Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	28.06B -30.7%
Revenue (ttm)	5.99B -2.2%
Net Income	972.56M -34.1%
EPS	0.49 -34.1%
Shares Out	1.98B
PE Ratio	29.17
Forward PE	30.20
Dividend	0.20 (1.40%)
Ex-Dividend Date	Sep 25, 2025

Volume	9,744,969
Average Volume	9,367,346
Open	14.30
Previous Close	14.26
Day's Range	14.15 - 14.32
52-Week Range	14.16 - 22.08
Beta	0.19
RSI	32.65
Earnings Date	Apr 30, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,205
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2025, SHA:600161's revenue was 6.17 billion, an increase of 2.26% compared to the previous year's 6.03 billion. Earnings were 1.09 billion, a decrease of -29.59%.